Metraipolis › archive › dc_8abe5ff1619a

Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials — Europe PMC PMID:41113338

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41113338
DOI
10.1016/j.ajpc.2025.101303
License (as archived)
solo-consultazione
Archived
2026-11-09T21:59:10.004Z
SHA-256 of the archived text
9135813f42890074210b52f1967679a1c78ae5ce1f370da4f7d70314f012bc67
Stable URL of this page
https://metraipolis.com/documento/dc_8abe5ff1619a

How to cite

Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials — Europe PMC PMID:41113338 — Europe PMC (en), https://europepmc.org/article/MED/41113338 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8abe5ff1619a (Metraipolis archive dc_8abe5ff1619a, sha256 9135813f42890074210b52f1967679a1c78ae5ce1f370da4f7d70314f012bc67)
BibTeX
@misc{dc8abe5ff1619a,
  title = {Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials — Europe PMC PMID:41113338},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41113338},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8abe5ff1619a; sha256 9135813f42890074210b52f1967679a1c78ae5ce1f370da4f7d70314f012bc67},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41113338. Agents can read the archived copy with the MCP tool read_document.